Exact Sciences (NASDAQ:EXAS) shares experienced a sharp 12.60% decline in after-hours trading on Wednesday, despite reporting better-than-expected second-quarter results. The molecular diagnostics company, known for its Cologuard colorectal cancer screening test, posted revenue of $811.085 million, surpassing the analyst consensus estimate of $774.338 million by 4.75%. The company also reported an adjusted loss per share of $0.01, beating expectations of a $0.19 loss.

While the top and bottom-line results exceeded Wall Street projections, investors appeared to focus on the company's continued losses. Exact Sciences reported a net loss of $1.185 million for the quarter, with income from operations at negative $2.148 million. This ongoing lack of profitability may have contributed to the stock's sharp decline, as shareholders might be growing impatient with the company's path to sustainable earnings.

Adding complexity to the financial picture, Exact Sciences announced the acquisition of exclusive rights to Freenome's colorectal cancer (CRC) tests. Under the agreement terms, Freenome is set to receive $75 million by November 2025. While this strategic move could potentially strengthen Exact Sciences' product portfolio, investors might be concerned about the deal's immediate financial impact and long-term return on investment. Furthermore, the company revealed that Freenome has submitted the final module for FDA approval, a development that could bring both opportunities and regulatory uncertainties. The market's negative reaction suggests that investors may need more clarity on how these strategic initiatives will translate into improved financial performance in the near term.